(Q48956010)

17 February 2018

title

Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease. (English)

1 reference

17 February 2018

1 reference

1 reference

6

1 reference

17 February 2018

author name string

Thibaud Thiollier

1

1 reference

17 February 2018

Caisheng Wu

2

1 reference

17 February 2018

Hugues Contamin

3

1 reference

17 February 2018

Qin Li

4

1 reference

17 February 2018

Jinlan Zhang

5

1 reference

17 February 2018

publication date

21 January 2016

1 reference

17 February 2018

published in

Synapse

1 reference

17 February 2018

volume

70

1 reference

17 February 2018

issue

6

1 reference

17 February 2018

page(s)

231-239

1 reference

17 February 2018

Effect of food and an antacid on quinidine bioavailability.

cites work

1 reference

Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease

21 January 2018

1 reference

Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis

21 January 2018

1 reference

Blood-brain barrier P-glycoprotein function in Alzheimer's disease.

21 January 2018

1 reference

The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies

21 January 2018

1 reference

Carbamazepine uptake into rat brain following intra-olfactory transport

21 January 2018

1 reference

Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian.

21 January 2018

1 reference

Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease

21 January 2018

1 reference

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

21 January 2018

1 reference

5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease

21 January 2018

1 reference

L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain

21 January 2018

1 reference

Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease.

21 January 2018

1 reference

Neuropharmacokinetics of a new alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) modulator, S18986 [(S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide], in the rat.

21 January 2018

1 reference

Alzheimer's disease and the Blood-Brain Barrier: Past, Present and Future

21 January 2018

1 reference

6-Hydroxydopamine-induced alterations in blood-brain barrier permeability

21 January 2018

1 reference

Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism.

21 January 2018

1 reference

Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease

21 January 2018

1 reference

Strategies to assess blood-brain barrier penetration

21 January 2018

1 reference

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model

21 January 2018

1 reference

Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium

21 January 2018

1 reference

Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia

21 January 2018

1 reference

Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys

21 January 2018

1 reference

L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys.

21 January 2018

1 reference

The blood-brain barrier/neurovascular unit in health and disease

21 January 2018

1 reference

Alzheimer Disease in the US Population

21 January 2018

1 reference

Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease

21 January 2018

1 reference

Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid.

21 January 2018

1 reference

L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.

21 January 2018

1 reference

Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery.

21 January 2018

1 reference

Blood-brain barrier dysfunction-induced inflammatory signaling in brain pathology and epileptogenesis

21 January 2018

1 reference

Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma

21 January 2018

1 reference

Blood-brain barrier dysfunction in parkinsonian midbrain in vivo

21 January 2018

1 reference

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

21 January 2018

1 reference

Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents.

21 January 2018

1 reference

CSF as a surrogate for assessing CNS exposure: an industrial perspective

21 January 2018

1 reference

Several major antiepileptic drugs are substrates for human P-glycoprotein

21 January 2018

1 reference

Comparison by microdialysis of striatal L-DOPA after its systemic administration in rats with probes implanted acutely or through a guide cannula.

21 January 2018

1 reference

Amyloid plaque core protein in Alzheimer disease and Down syndrome

21 January 2018

1 reference

Priorities in Parkinson's disease research

21 January 2018

1 reference

Stimulation of bone formation in vitro and in rodents by statins

21 January 2018

1 reference

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia

21 January 2018

1 reference

The digestive neuronal-glial-epithelial unit: a new actor in gut health and disease.

21 January 2018

1 reference

Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia

21 January 2018

1 reference

Carbamazepine is not a substrate for P-glycoprotein

21 January 2018

1 reference

Blood-brain barrier delivery

21 January 2018

1 reference

Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies

21 January 2018

1 reference

Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease.

21 January 2018

1 reference

Blood-brain barrier alterations in ageing and dementia

21 January 2018

1 reference

PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking

21 January 2018

1 reference

P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain

21 January 2018

1 reference

The role of blood-brain barrier studies in the pharmaceutical industry

21 January 2018

1 reference

Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept

21 January 2018

1 reference

In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.

21 January 2018

1 reference

Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease.

21 January 2018

1 reference

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3.

21 January 2018

1 reference

Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics

21 January 2018

1 reference

Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children

21 January 2018

1 reference

Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase

21 January 2018

1 reference

Transport of carbamazepine and drug interactions at blood-brain barrier

21 January 2018

1 reference

Alteration in P-glycoprotein functionality affects intrabrain distribution of quinidine more than brain entry-a study in rats subjected to status epilepticus by kainate

21 January 2018

1 reference

Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non-human primates: a cytochrome oxidase histochemistry study.

21 January 2018

1 reference

Inflammatory events at blood-brain barrier in neuroinflammatory and neurodegenerative disorders: implications for clinical disease

21 January 2018

1 reference

Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease.

21 January 2018

1 reference

Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine

21 January 2018

1 reference

The blood-brain barrier in brain homeostasis and neurological diseases

21 January 2018

1 reference

Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.

21 January 2018

1 reference

Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets

21 January 2018

1 reference

Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/SYN.21889

1 reference

17 February 2018

1 reference

17 February 2018